| Literature DB >> 29729667 |
Ajit Kumar Passari1, Vincent Vineeth Leo1, Preeti Chandra2, Brijesh Kumar2, Chandra Nayak3, Abeer Hashem4,5, Elsayed Fathi Abd Allah6, Abdulaziz A Alqarawi6, Bhim Pratap Singh7.
Abstract
BACKGROUND: Actinobacteria from freshwater habitats have been explored less than from other habitats in the search for compounds of pharmaceutical value. This study highlighted the abundance of actinobacteria from freshwater sediments of two rivers and one lake, and the isolates were studied for their ability to produce antimicrobial bioactive compounds.Entities:
Keywords: Actinobacteria; GC–MS; NRPS; PKSII; UPLC–ESI–MS/MS; VOCs; phzE
Mesh:
Substances:
Year: 2018 PMID: 29729667 PMCID: PMC5935920 DOI: 10.1186/s12934-018-0912-0
Source DB: PubMed Journal: Microb Cell Fact ISSN: 1475-2859 Impact factor: 5.328
Fig. 4MRM extracted ion chromatogram of reference analyte: a trimethoprim, b fluconazole, c ketoconazole, d rifampicin
Fig. 1Maximum likelihood phylogenetic tree constructed using Tamura-Nei model based on 16S rRNA gene sequences of actinobacteria showing the phylogenetic relationship between the isolates with closest type strain sequences. Numbers at branches indicate bootstrap values in 1000 replicates
Fig. 2Abundance of actinobacterial isolates in three fresh water systems
Antimicrobial activity of selected strains of actinobacteria
| Strain | Antibacterial properties | Yeast | Biosynthetic genes | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| PKS-II | NRPS | ||
| 9.40 ± 0.03a | 12.0 ± 0.06a | 9.00 ± 0.06a | 13.2 ± 0.10a | 12.5 ± 0.2a | 12.5 ± 0.20a | + | + | − | |
| 9.50 ± 0.01a | 10.0 ± 0.10bc | 10.0 ± 0.10bc | 12.7 ± 0.10a | 12.5 ± 0.1a | 11.5 ± 0.50bc | − | − | − | |
| 15.0 ± 0.01bc | 11.5 ± 0.15a | 8.00 ± 0.05bde | 10.8 ± 0.10bc | 8.4 ± 0.00bc | 15.5 ± 0.05bde | + | + | − | |
| 13.0 ± 0.30bde | 10.0 ± 0.04bc | 6.60 ± 0.40bdf | 6.20 ± 0.20bde | 15.9 ± 0.2bde | 13.8 ± 0.10bdfg | − | + | + | |
| 9.00 ± 0.30a | 8.50 ± 0.05bde | 9.20 ± 0.25a | 18.8 ± 0.10bdfg | 14.4 ± 0.2bdfg | 12.9 ± 0.05a | + | + | − | |
| 8.10 ± 0.10bdf | 7.00 ± 0.10bdf | 8.00 ± 0.10bde | 14.3 ± 0.10bdfh | 14.2 ± 0.1bdfg | 13.1 ± 0.10bdfh | + | + | + | |
Mean (± SD) followed by the same letter(s) in each column are not significant different at P < 0.05 using Duncan’s new multiple range test
EC50 of six Streptomyces strains against six pathogens
| Strain | EC50 mg/ml | |||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| 0.235 | 0.231 | 0.110 | 0.227 | 0.051 | 0.069 | |
|
| 1.673 | 2.353 | 1.085 | 0.804 | 0.331 | 0.900 |
| 0.086 | 0.144 | 0.070 | 0.009 | 0.286 | 0.070 | |
| 0.260 | 0.015 | 0.015 | 0.278 | 0.950 | 1.195 | |
|
| 0.056 | 0.267 | 0.040 | 0.170 | 0.003 | 1.600 |
|
| 0.102 | 0.050 | 0.138 | 0.650 | 0.190 | 0.075 |
Fig. 3Maximum likelihood (ML) phylogenetic tree constructed using amino acid sequences for a PKS type II gene; b NRPS gene and c phzE gene. The scale bar represents the amino acid changes
Antibiotics content of six selected strains (μg/g)
| Strain no. | Trimethoprim | Fluconazole | Ketoconazole | Rifamycin |
|---|---|---|---|---|
| 17.0 | 8.0 | 29.0 | 51.0 | |
|
| 21.0 | 17.0 | 50.0 | 74.0 |
|
| 39.0 | 5.0 | 28.0 | 78.0 |
|
| 27.0 | 16.0 | 35.0 | 68.0 |
| 26.0 | 10.0 | 49.0 | 86.0 | |
| 28.0 | 6.0 | 32.0 | 64.0 |
Fig. 5MS/MS Spectra of reference analytes; a trimethoprim, b fluconazole, c ketoconazole, d rifampicin (as per [21])